Verdemed is a Canadian pharmaceutical cannabis company that is dedicated to bringing affordable cannabinoid-based medications to doctors and patients in Latin America. With a focus on product formulations of cannabinoid pharmaceuticals already approved in Canada, Europe, and the USA, Verdemed aims to meet the medical needs of Latin Americans in all authorized jurisdictions. The company is uniquely positioned to overcome the regulatory obstacles in Latin America by leveraging its Canadian-derived pharmaceutical products.

Canada, with its robust regulatory framework, has set the standard for patient safety and reliable treatments with medical cannabis products. Verdemed operates with the goal of improving the health of millions of patients in Latin America by introducing a wide range of fully approved cannabinoid-based medications. As the partner of choice for global cannabis pharmaceutical companies, Verdemed is building alliances to bring new medical cannabis products to the Latin American market.

Led by an experienced team and collaborating with renowned experts in the pharmaceutical industry, Verdemed ensures the delivery of safe and proven pharmaceutical products to doctors and patients across the region